Immunotherapy of Sepsis: Blind Alley or Call for Personalized Assessment?
| Autor: | Miroslav Prucha, R Zazula, Stefan Russwurm |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Proteomics
0301 basic medicine medicine.medical_specialty Genotype medicine.medical_treatment Immunology Apoptosis Inflammation Sepsis 03 medical and health sciences 0302 clinical medicine Adrenal Cortex Hormones Intensive care Animals Humans Immunology and Allergy Medicine Precision Medicine Intensive care medicine Cause of death Immunosuppression Therapy business.industry Toll-Like Receptors Immunoglobulins Intravenous 030208 emergency & critical care medicine Immunosuppression Genomics General Medicine Immunotherapy Precision medicine medicine.disease Clinical trial Intensive Care Units Phenotype 030104 developmental biology Immune System Cytokines Intercellular Signaling Peptides and Proteins medicine.symptom business Biomarkers |
| Zdroj: | Archivum Immunologiae et Therapiae Experimentalis. 65:37-49 |
| ISSN: | 1661-4917 0004-069X |
| Popis: | Sepsis is the most frequent cause of death in noncoronary intensive care units. In the past 10 years, progress has been made in the early identification of septic patients and their treatment. These improvements in support and therapy mean that mortality is gradually decreasing, however, the rate of death from sepsis remains unacceptably high. Immunotherapy is not currently part of the routine treatment of sepsis. Despite experimental successes, the administration of agents to block the effect of sepsis mediators failed to show evidence for improved outcome in a multitude of clinical trials. The following survey summarizes the current knowledge and results of clinical trials on the immunotherapy of sepsis and describes the limitations of our knowledge of the pathogenesis of sepsis. Administration of immunomodulatory drugs should be linked to the current immune status assessed by both clinical and molecular patterns. Thus, a careful daily review of the patient's immune status needs to be introduced into routine clinical practice giving the opportunity for effective and tailored use of immunomodulatory therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink